Jul. 9 at 2:05 PM
$BIAF And even more:
Reimbursement progress – Any positive updates regarding insurance coverage or reimbursement would likely be viewed as a major long-term catalyst.
Additional clinical publications or case studies – More peer-reviewed evidence supporting CyPath Lung's ability to detect early-stage lung cancer or reduce unnecessary invasive procedures.
Cleveland Clinic exposure – Follow-up publicity or physician interest resulting from CyPath Lung's participation in the Cleveland Clinic's early lung cancer detection symposium.
COPD / Asthma diagnostic pipeline – Updates on the Brooke Army Medical Center collaboration evaluating biomarkers for COPD and asthma, demonstrating broader platform potential beyond lung cancer.
AI / platform messaging – Continued emphasis that CyPath Lung combines flow cytometry with machine learning to improve diagnostic accuracy, helping differentiate it from traditional screening methods.
